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ABSTRACT 
Optimization of an essentially inactive 3,4-dihydro-2H-pyrano[3,2-c]quinoline 
carboxylic ester derivative as acetylcholinesterase (AChE) peripheral anionic site 
(PAS)-binding motif by double O → NH bioisosteric replacement, combined with 
molecular hybridization with the AChE catalytic anionic site (CAS) inhibitor 6-
chlorotacrine and molecular dynamics-driven optimization of the length of the linker 
has resulted in the development of the trimethylene-linked 1,2,3,4-
tetrahydrobenzo[h][1,6]naphthyridine–6-chlorotacrine hybrid 5a as a picomolar 
inhibitor of human AChE (hAChE). The tetra-, penta-, and octamethylene-linked 
homologues 5b–d have been also synthesized for comparison purposes, and found to 
retain the nanomolar hAChE inhibitory potency of the parent 6-chlorotacrine. Further 
biological profiling of hybrids 5a–d has shown that they are also potent inhibitors of 
human butyrylcholinesterase and moderately potent Aβ42 and tau anti-aggregating 
agents, with IC50 values in the submicromolar and low micromolar range, respectively. 
Also, in vitro studies using an artificial membrane model have predicted a good brain 
permeability for hybrids 5a–d, and hence, their ability to reach their targets in the 
central nervous system. The multitarget profile of the novel hybrids makes them 
promising leads for developing anti-Alzheimer drug candidates with more balanced 
biological activities. 
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1. Introduction 
Alzheimer’s disease (AD) currently represents one of the most important unmet medical 
needs worldwide. Worryingly, because prevalence and mortality figures associated with 
AD will keep increasing, this condition will be even more pronounced in the upcoming 
decades, unless efficient disease-modifying drugs become available [1]. 
Current treatments for AD involve the use of acetylcholinesterase (AChE) inhibitors 
(donepezil, rivastigmine and galantamine) or NMDA receptor antagonists (memantine), 
which restore neurotransmitter deficits that are responsible for the symptomatic phase of 
the disease (cognitive, functional, and neuropsychiatric deficits) that appears a decade 
or more after the onset of the neurodegenerative process.  
It is becoming increasingly apparent that the simultaneous modulation of several crucial 
targets that play early roles in the neuropathogenic process is a promising approach to 
derive effective drugs that can modify the course of AD [3,4]. Obviously, 
administration of these multitarget drugs depends on a precise knowledge of the timing 
of the critical neuropathologies to be hit and on the development of suitable biomarkers 
that enable timely therapeutic interventions and the assessment of their impact on AD 
progression. Whereas these important issues are addressed [2,5,6], the parallel 
development of multitarget drugs hitting different combinations of key biological 
targets should be actively pursued. 
Neuropathologies related to the β-amyloid peptide (Aβ) and tau protein are thought to 
be at the root of the neurodegenerative process [2]. Also, AChE seems to play a role in 
the early phases of the disease, inasmuch as it can bind to Aβ, thereby accelerating its 
aggregation into oligomers and fibrils and increasing the neurotoxicity of Aβ aggregates 
[7]. The Aβ proaggregating action of AChE has been reported to reside in its peripheral 
anionic site (PAS) [7c], which is located at the mouth of a 20 Å deep gorge that leads to 
the catalytic anionic site (CAS) of the enzyme [8].  
We have recently developed a new family of potent AChE inhibitors able to 
simultaneously bind at the CAS and PAS of the enzyme, i.e. dual binding site inhibitors, 
which were designed by molecular hybridization of the novel 3,4-dihydro-2H-
pyrano[3,2-c]quinoline scaffold of ester 1 and the potent AChE CAS inhibitor 6-
chlorotacrine, 2 (Fig. 1) [9]. The most potent hybrid of the series, compound 3 (Fig. 1) 
retained the high human AChE inhibitory activity of the parent 6-chlorotacrine (3: IC50 
= 7 nM in human erythrocyte AChE; IC50 = 19 nM in human recombinant AChE 
(hAChE)), and additionally exhibited a potent inhibitory activity of human 
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butyrylcholinesterase (hBChE) and a weak Aβ antiaggregating activity (29% inhibition 
of AChE-induced Aβ40 aggregation at 100 µM and 21% inhibition of self-induced 
Aβ42 aggregation at 50 µM) [9]. 
 
Please, insert here Fig. 1. 
 
Even though the 5-(4-chlorophenyl)-3,4-dihydro-2H-pyrano[3,2-c]quinoline moiety of 
3 might establish π–π stacking interactions with the aromatic PAS residues Trp286 and 
Tyr72 (hAChE numbering), concomitant to the interactions of the 6-chlorotacrine unit 
at the CAS, the 5-(4-chlorophenyl)-3,4-dihydro-2H-pyrano[3,2-c]quinoline ester 1, used 
as synthetic precursor of 3, was found to be essentially inactive as AChE inhibitor. With 
the aim of optimizing this tricyclic scaffold as a PAS-binding moiety, we recently 
designed a family of tetrahydrobenzo[h][1,6]naphthyridines, which mainly resulted 
from the substitution of the oxygen atom at position 1 of the 3,4-dihydro-2H-
pyrano[3,2-c]quinoline system of ester 1 by an amine nitrogen atom [10]. The rationale 
behind this structural modification was that the increased basicity of the pyridine 
nitrogen atom would enable i) its protonation at physiological pH, and hence, ii) the 
establishement of cation–π interactions, apart from π–π stacking, with the aromatic PAS 
residues. Indeed, the most potent compound of the series, 4 (Fig. 1), resulting from a 
double O → NH bioisosteric replacement from ester 1 at position 1 and at the side chain 
in position 9, exhibited a nanomolar hAChE inhibitory activity (IC50 = 65 nM) [10]. 
Molecular dynamics (MD) simulations confirmed the expected binding of the tricyclic 
moiety of 4 at the AChE PAS (cation–π / π–π interactions with Trp286) and hydrogen 
bond between the protonated pyridine nitrogen atom and the hydroxyl group of the PAS 
residue Tyr72) as well as additional interactions of the amide function at position 9 with 
midgorge residues (hydrogen bond between the amide NH group and the hydroxyl 
group of Tyr124) [10]. 
Once the PAS-binding moiety had been optimized, we inferred that molecular 
hybridization with the CAS binder 6-chlorotacrine should provide further improvement 
of the AChE inhibitory activity. The disposition of the amide chain at position 9 of the 
tetrahydrobenzo[h][1,6]naphthyridine 4 along the midgorge, with its nitrogen atom at a 
distance of ~6 Å from the position occupied by the exocyclic amino group of tacrine in 
its complex with Torpedo californica AChE (Fig. 2) [11], suggested that a linker of 3 
methylenes should be optimal to connect both moieties retaining all their interactions 
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with AChE residues all along the enzyme gorge. Thus, the 
tetrahydrobenzo[h][1,6]naphthyridine–6-chlorotacrine hybrid 5a (Fig. 1) was rationally 
designed as a novel multiple-site AChE inhibitor, bearing optimized PAS-binding 
moiety and tether length. 
 
Please, insert here Fig. 2. 
 
Herein, we describe the synthesis of the tetrahydrobenzo[h][1,6]naphthyridine–6-
chlorotacrine hybrid 5a and its longer tetra-, penta-, and octa-methylene-linked 
homologues 5b–d, the evaluation of their inhibitory activities against hAChE and 
hBChE, and the study of their binding mode to hAChE by MD simulations. To further 
expand the potential multitarget profile of hybrids 5a–d, their inhibitory activities 
against the aggregation of Aβ42 and tau protein in intact Escherichia coli cells, as a 
simplified in vivo model of aggregation of amyloidogenic proteins, were also evaluated. 
Moreover, the brain penetration of these hybrids, and therefore the ability to reach their 
targets at the central nervous system (CNS), was assessed by a parallel artificial 
membrane permeation assay (PAMPA-BBB). 
 
2. Results and discussion 
2.1. Synthesis of the tetrahydrobenzo[h][1,6]naphthyridine–6-chlorotacrine hybrids 
Apart from the rationally designed trimethylene-linked hybrid 5a, we planned the 
synthesis of the longer tetra- and penta-methylene homologues 5b and 5c, still bearing 
relatively short linkers. We also envisioned the synthesis of the octamethylene-linked 
analogue 5d, mainly for comparison with the octamethylene-linked 3,4-dihydro-2H-
pyrano[3,2-c]quinoline-based hybrid 3, to gain further insight into the effect of the O → 
NH bioisosteric replacement at position 1 of the tricyclic system, while keeping the 
same tether length. 
For the synthesis of hybrids 5a–d, we used as starting material the N-Boc-protected 
tetrahydrobenzo[h][1,6]naphthyridine 6, readily available by a multicomponent Povarov 
reaction between 4-chlorobenzaldehyde, ethyl 4-aminobenzoate and N-Boc-3,4-
dihydro-2H-pyridine under the catalysis of Sc(OTf)3 in acetonitrile [12], followed by 
DDQ oxidation [13] of the resulting diastereomeric mixture of 
octahydrobenzo[h][1,6]naphthyridines [10]. Saponification of ester 6, followed by 
treatment of the resulting carboxylate with an Et2O solution of HCl afforded the 
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corresponding carboxylic acid, which was isolated as the naphthyridine hydrochloride. 
Coupling of the carboxylic acid with the known aminoalkyltacrine derivatives 7a–d 
[14], using HOBt and EDC in the presence of Et3N in a 10:1 mixture EtOAc/DMF, 
followed by silica gel column chromatography purification afforded the expected N-
Boc-protected amides, in some cases together with directly deprotected amides (5a and 
5c). Treatment of the N-Boc-protected amides with 4 M HCl in dioxane at room 
temperature afforded the target amides 5a–d in 34-80% total overall yields from ester 6 
(Scheme 1). 
The novel tetrahydrobenzonaphthyridine–6-chlorotacrine hybrids 5a–d were fully 
characterized in the form of dihydrochloride salts through their spectroscopic data (IR, 
1H and 13C NMR) and HRMS and their purity was assessed by elemental analysis. The 
biological characterization was also performed with the dihydrochloride salts. 
 
Please, insert here Scheme 1. 
 
2.2. Acetylcholinesterase inhibition 
2.2.1. Evaluation of AChE inhibitory activity 
The inhibitory activity of the novel hybrids 5a–d against hAChE was evaluated by the 
method of Ellman et al. [15]. The 3,4-dihydro-2H-pyrano[3,2-c]quinoline derivatives 1 
and 3, as well as 6-chlorotacrine, 2, were also evaluated under the same assay 
conditions as reference compounds. Also, the reported activity of compound 4 [10] was 
considered for comparison purposes. 
All the tetrahydrobenzonaphthyridine–6-chlorotacrine hybrids turned out to be very 
potent inhibitors of hAChE (Table 1). Indeed, in agreement with the rational design 
strategy, the trimethylene-linked hybrid 5a was the most potent hAChE inhibitor of the 
series, exhibiting a surprising picomolar IC50 value (IC50 = 6.27 pM). The highly potent 
inhibitory activity of 5a is indicative of the success of the rational design strategy, in 
terms of both the molecular hybridization and the optimization of the tether length. On 
the one hand, molecular hybridization has been successful because 5a is roughly 1000-
fold and >10000-fold more potent than the parent compounds 6-chlorotacrine, 2, and 4, 
respectively (Table 1). On the other hand, the MD-driven optimization of the tether 
length has been also successful, inasmuch the trymethylene-linked hybrid 5a is much 
more potent than the tetra-, penta-, and octa-methylene-linked counterparts (>2000-fold 
more potent than 5b and 5c and >300-fold more potent than 5d). 
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Please, insert here Table 1. 
 
The O → NH bioisosteric replacement, which had proven to be successful in the 
optimization from the 3,4-dihydro-2H-pyrano[3,2-c]quinoline ester 1 to the 
tetrahydrobenzo[h][1,6]naphthyridine amide 4 [10], has been also successful in the 
corresponding hybrids with 6-chlorotacrine, the tetrahydrobenzo[h][1,6]naphthyridine-
based hybrid 5d being roughly 10-fold more potent than the 3,4-dihydro-2H-
pyrano[3,2-c]quinoline-based hybrid 3, with the same tether length (Table 1). 
Overall, hybrid 5a constitutes one of the most potent noncovalent inhibitors of hAChE 
so far reported, even though a few examples of other picomolar or even femtomolar 
inhibitors of AChE have also been described [14a,16]. 
 
2.2.2. Binding mode within AChE: Molecular modelling studies 
To shed light on the structural basis of the surprisingly high AChE inhibitory activity 
determined for compound 5a, the binding mode to hAChE was explored by means of 
MD simulations, taking advantage of the X-ray crystallographic structure of the hAChE 
complex with huprine W (PDB entry 4BDT [17]). The initial pose of the ligand was 
guided by the structural information available for the binding mode of huprine X to 
Torpedo californica AChE (PDB entry 1E66 [18]), which matches well the structure of 
huprine W bound to hAChE, and by the recently reported binding mode of compound 4 
[10]. 
The analysis of the 100 ns MD trajectory supported the structural integrity and stability 
of the ligand bound to the hAChE gorge. Thus, with the sole exception of a slight 
reorientation of the tetrahydrobenzo[h][1,6]naphthyridine moiety in the PAS, which was 
originated from a conformational change in the loop defined by residues 289–292, the 
RMSD of the ligand remained fully stable during the last 60 ns of the trajectory (Fig. 
S1, Supplementary Material). The hybrid 5a establishes a complex network of 
interactions with the residues of the binding site (Fig. 3). As expected, the 6-
chlorotacrine moiety was tightly bound in the CAS due to the cation–π interactions with 
the aromatic rings of Trp86 and Tyr337 (average distances of 3.9 Å between the indole 
or phenol rings and the aminoacridine unit) and the hydrogen bond of the protonated 
acridine nitrogen atom with the carbonyl oxygen of His447 (average distance of 2.9 Å). 
On the other hand, the tetrahydrobenzo[h][1,6]naphthyridine moiety was firmly stacked 
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against Trp286, thus enabling the formation of a cation–π interaction between the 
protonated quinoline nitrogen atom and the indole ring of Trp286. The binding of this 
moiety was also assisted by transient hydrogen bond interactions between the NH group 
and the hydroxyl oxygen of Tyr72. The most remarkable finding concerns the 
interactions formed by the amide group in the tether, as the amide NH group is involved 
in a hydrogen bond with Asp74 (average distance of 3.6 Å), which is in turn hydrogen-
bonded to the hydroxyl group of Tyr341 (average distance of 2.8 Å), while the amide 
carbonyl oxygen forms either direct or water-mediated interactions with the hydroxyl 
group of Tyr337 (average distance of 4.9 Å). As a further test, the binding free energy 
of compound 5a was determined with the Solvated Interaction Energy (SIE) method 
[19], which relies on MM/PBSA calculations in conjunction with weighting scaling 
factors for the free energy components suitably parameterized to reproduce the 
experimental binding affinities for a diverse set of protein–ligand complexes. The SIE 
binding affinity obtained for compound 5a is –12.5 kcal/mol (Table S1, Supplementary 
Material), which is 4 kcal/mol lower than that determined for compound 4 (–8.5 
kcal/mol [10]), which is in agreement with the ~104 ratio between the IC50 values 
reported in Table 1. 
These findings provide a basis to explain the abrupt change in inhibitory activity 
between compounds 5a and 5b, as the enlargement of the oligomethylene chain 
between tacrine and the amide group would disrupt the interactions with the midgorge 
residues. On the other hand, the amide group that is present in the tether of some 
tacrine–indole heterodimers reported by Muñoz-Ruiz et al. as picomolar AChE 
inhibitors was also suggested to participate in a complex network of interactions with 
midgorge residues [14a]. In the most potent tacrine–indole heterodimer the amide 
group, located at six methylene groups from the tacrine unit, was suggested to interact 
with Tyr124 and Tyr337. In hybrid 5a the shortening of the chain to three methylenes 
enables the formation of a distinct interaction pattern with Asp74 and Tyr337. Overall, 
these findings reinforce the significant contribution played by the midgorge in 
complementing both PAS and CAS and modulating the affinity of AChE inhibitors. 
 
Please, insert here Fig. 3. 
 
2.3. Butyrylcholinesterase inhibition 
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BChE is partly responsible for acetylcholine hydrolysis and hence, for the cholinergic 
deficit of AD patients, especially in advanced stages of the disease, when the levels of 
AChE in CNS markedly decrease. Thus, BChE also represents a biological target of 
interest for AD treatment [20]. The BChE inhibitory activity of hybrids 5a–d against 
hBChE was evaluated by the method of Ellman et al. [15]. 
The parent compounds 6-chlorotacrine, 2, and 4 are selective inhibitors of hAChE, 
albeit still exhibiting a moderately potent hBChE inhibitory activity, with IC50 values in 
the submicromolar range. Not unexpectedly, hybrids 5a–d were also more potent 
against hAChE than hBChE, displaying submicromolar IC50 values for hBChE 
inhibition (Table 1). In this case, molecular hybridization resulted in an increased 
hBChE inhibitory activity relative to the parent compound 4 (3–8-fold) but in a slightly 
decreased potency relative to 6-chlorotacrine, 2, with the exception of hybrid 5a, which 
was equipotent to 6-chlorotacrine. 
The length of the linker has little influence on the hBChE inhibitory activity. Only a 
slight trend toward decreased potency with increased tether length was observed, the 
shorter homologue 5a being 1.7-, 2.8-, and 2.4-fold more potent than the longer 
counterparts 5b, 5c, and 5d, respectively. Finally, the O → NH bioisosteric replacement 
had little influence on the hBChE inhibitory activity, the octamethylene-linked 3,4-
dihydro-2H-pyrano[3,2-c]quinoline- and tetrahydrobenzo[h][1,6]naphthyridine-based 
hybrids 3 and 5d roughly displaying the same potency (Table 1). 
 
2.4. Aβ42 and tau aggregation inhibition 
The aggregation of the amyloidogenic proteins Aβ, especially the most aggregation-
prone and neurotoxic 42 amino acid form thereof (Aβ42), and tau are widely thought to 
constitute early pathogenic events in AD, and hence, they are the target of many drug 
candidates purported to modify the natural course of the disease [21]. 
We have recently developed a new methodology for the evaluation of the effects of 
putative inhibitors on the aggregation and subsequent formation of insoluble inclusion 
bodies of any amyloidogenic protein that can be overexpressed in E. coli cells [22]. The 
method relies on monitoring the changes in the fluorescence of Thioflavin S (Th-S) that 
are produced upon binding to amyloid aggregates rich in β-sheet structures. Compounds 
that are able to cross the membranes of E. coli cells and inhibit the aggregation of 
overexpressed amyloidogenic proteins will lead to a decrease in the fluorescence of Th-
S. This method is fast, simple and inexpensive, as it avoids the use of synthetic peptides. 
 10
We have successfully used this method for the evaluation of inhibitors of Aβ42 and tau 
aggregation. Interestingly, the results obtained in the screening of Aβ42 aggregation 
inhibitors correlated very well with the results previously reported from in vitro assays 
using synthetic peptides, thereby validating this methodology [22]. 
The inhibitory activity of hybrids 5a–d against Aβ42 and tau aggregation was assessed 
using this methodology. In general, very similar results and SAR trends were found for 
both activities. At 10 µM, hybrids 5a–d exhibited percentages of inhibition in the ranges 
52–77% and 41–69% against Aβ42 and tau aggregation, respectively (Table 1). 
Molecular hybridization led to increased Aβ42 and tau anti-aggregating activities, 
hybrids 5a–d being more potent than 6-chlorotacrine (5–7-fold more potent against 
Aβ42 aggregation and 30–50-fold more potent against tau aggregation). The parent 
compound 4 could not be tested in these assays, but in in vitro tests it had been found to 
be a weak inhibitor of Aβ42 aggregation (15% inhibition at 10 µM) [10], so presumably 
hybrids 5a–d are also more potent than 4. 
The length of the linker seemed to have a subtle effect on Aβ42 and tau anti-aggregating 
activities. These activities slightly increased with the tether length so that the longer 
homologue 5d was 1.5-fold more potent than the shorter counterpart 5a for both 
activities. On the other hand, the O → NH bioisosteric replacement had a similar effect 
on both activities, the tetrahydrobenzo[h][1,6]naphthyridine-based hybrid 5d being 
roughly 1.5-fold more potent than the 3,4-dihydro-2H-pyrano[3,2-c]quinoline-based 
hybrid 3 for Aβ42 and tau aggregation inhibition. 
The parallel results obtained for these hybrids against both Aβ42 and tau aggregation 
further support the notion that diseases based on the pathological aggregation of one or 
several amyloidogenic proteins might share common mechanisms and might be 
confronted with common therapeutic interventions [23]. 
Overall, hybrids 5a–d can be considered as moderately potent dual Aβ42 and tau anti-
aggregating compounds, with IC50 values that must lie around or below 10 µM. Because 
these anti-aggregating activities have been determined without involving the presence of 
AChE, the high AChE inhibitory activity of hybrids 5a–d cannot be responsible for 
their Aβ42 and tau anti-aggregating activities, which might be ascribed, instead, to a 
direct interaction with Aβ42 and tau. The precise mechanisms through which these 
hybrids bind Aβ42 and tau and/or exert their anti-aggregating activities are unknown, 
even though it has been reported that the presence of several aromatic moieties with 
extended π-conjugated systems (including biphenyls and phenyl-substituted 
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benzoheteroaromatic systems, similar to the phenylquinoline moiety present in hybrids 
5a–d) may enable binding to Aβ42 [24]. 
The dual Aβ42 and tau anti-aggregating profile is of much interest for disease-
modifying anti-Alzheimer agents. However, it must be recognized that the anti-
aggregating activities of hybrids 5a–d are not well balanced relative to their 
cholinesterase inhibitory activities, especially AChE and particularly in the case of its 
picomolar inhibitor 5a, which represents an important issue in multitarget compounds. 
 
2.5. Blood–brain barrier permeation assay 
Anti-Alzheimer drug candidates, like any other CNS drug, must be able to efficiently 
enter into the brain, which requires a good ability to cross the blood–brain barrier 
(BBB) and a low P-glycoprotein efflux liability [25]. The large molecular weight of 
hybrids 5a–d (>500) might compromise their ability to cross biological membranes, 
including BBB [26]. However, a number of distinct anti-Alzheimer hybrid compounds 
with molecular weights over 500 have shown good oral availability and/or brain 
permeability in ex vivo and in vivo studies in mice [27]. Indeed, the positive results 
obtained for the hybrids 5a–d in the aggregation studies in E. coli cells were already 
indicative of their ability to cross biological membranes, but a more accurate 
determination of their ability to cross the BBB was necessary. In this light, the brain 
permeability of the hybrids 5a–d was predicted using an in vitro model of passive 
transcellular permeation, namely the widely known PAMPA-BBB assay [28]. Thus, the 
in vitro permeability (Pe) through a lipid extract of porcine brain was determined using 
a mixture of phosphate-buffered saline (PBS)/EtOH (70:30). Assay validation was made 
by comparing the experimental and reported permeability values of 14 commercial 
drugs (Table S2, Supplementary Material), which provided a good linear correlation: Pe 
(exp) = 1.5010 Pe (lit) – 0.8618 (R2 = 0.9199). Using this equation and the limits 
established by Di et al. for BBB permeation [28], the following ranges of permeability 
were established:  Pe (10−6 cm s−1) > 5.1 for compounds with high BBB permeation 
(CNS+); Pe (10−6 cm s−1) < 2.1 for compounds with low BBB permeation (CNS−); and 
5.1 > Pe (10−6 cm s−1) > 2.1 for compounds with uncertain BBB permeation (CNS+/−). 
All the tetrahydrobenzo[h][1,6]naphthyridine–6-chlorotacrine hybrids, 5a–d, were 
predicted to be able to cross the BBB. The measured Pe values for 5a–d were found to 
slightly increase with the tether length, and hence, with lipophilicity, and were clearly 
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above the threshold for high BBB permeation (Table 1), thereby anticipating their 
ability to enter the brain and reach their different CNS targets. 
Of note, the predicted in vitro ability of the novel hybrids to cross the BBB was also 
confirmed through the BBB permeation index obtained using a recently reported in 
silico multiclassification method (Table 2), which was developed utilizing a 
comprehensive data set containing around 12000 diverse compounds [29]. This method 
was also used to assess the intestinal absorption of the novel compounds, which was 
predicted to be positive in all cases. Finally, the predicted rat acute toxicity of the 
hybrids was clearly lower than that predicted for the anti-Alzheimer AChE inhibitor 
tacrine, thereby supporting the safety of these compounds (Table 2). 
 
3. Conclusion 
In this work we have further advanced in the hit-to-lead optimization process that, 
starting from the 3,4-dihydro-2H-pyrano[3,2-c]quinoline carboxylic ester 1, had led to 
the potent hAChE inhibitors 3 [9] and 4 [10] by molecular hybridization with 6-
chlorotacrine and by double O → NH bioisosteric replacement, respectively. Herein, 
combination of the optimized AChE PAS-binding moiety present in 4, molecular 
hybridization with 6-chlorotacrine, and a MD-driven optimization of the tether length 
has led to the discovery of the 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine–6-
chlorotacrine hybrid 5a as a picomolar inhibitor of hAChE. 
Apart from 5a, other three longer homologues, i.e. 5b–d, have been also synthesized 
and found to be potent inhibitors of hAChE, exhibiting IC50 values in the low 
nanomolar range. Like the parent compounds 6-chlorotacrine, 2, and the 
tetrahydrobenzo[h][1,6]naphthyridine 4, hybrids 5a–d have been found to be selective 
for hAChE vs. hBChE inhibition, albeit still keeping a potent hBChE inhibitory activity. 
Very interestingly, these hybrids turned out to be moderately potent dual inhibitors of 
Aβ42 and tau aggregation in intact E. coli cells, with IC50 values in the low micromolar 
range. Taking into account all the tested activities, hybrid 5d, with the most potent 
Aβ42 and tau anti-aggregating activities, is likely the hybrid of the series with the most 
interesting multitarget profile. Notwithstanding that better balanced potencies at their 
different targets would have been desirable, the multitarget profile of the novel hybrids, 
together with their predicted ability to cross the BBB, make them interesting anti-
Alzheimer lead compounds. 
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4. Experimental part 
4.1. Chemistry. General methods.  
Melting points were determined in open capillary tubes with a MFB 595010M 
Gallenkamp melting point apparatus. Recrystallization solvents from which the 
analytical samples have been obtained are indicated after the melting points. 400 MHz 
1H NMR and 500 MHz 1H/125.8 MHz 13C NMR spectra were recorded on Varian 
Gemini 400 and Varian Mercury 500 spectrometers, respectively. The chemical shifts 
are reported in ppm (δ scale) and coupling constants are reported in Hertz (Hz). 
Assignments given for the NMR spectra of the new compounds have been carried out 
by comparison with the NMR data of the precursor ester 6 and the hybrid compound 5d 
which in turn, were assigned on the basis of DEPT, COSY 1H/1H (standard procedures), 
and COSY 1H/13C (gHSQC or gHMBC sequences) experiments. IR spectra were run on 
a Perkin-Elmer Spectrum RX I spectrophotometer, using the Attenuated Total 
Reflectance (ATR) technique. Absorption values are expressed as wave-numbers (cm−
1); only significant absorption bands are given. Column chromatography was performed 
on silica gel 60 AC.C (35−70 µM, SDS, ref 2000027). Thin-layer chromatography was 
performed with aluminum-backed sheets with silica gel 60 F254 (Merck, ref 1.05554), 
and spots were visualized with UV light and 1% aqueous solution of KMnO4. NMR 
spectra of all of the new compounds were performed at the Centres Científics i 
Tecnològics of the University of Barcelona (CCiTUB), while elemental analyses and 
high resolution mass spectra were carried out at the Microanalysis Service of the IIQAB 
(CSIC, Barcelona, Spain) with a Carlo Erba model 1106 analyzer, and at the CCiTUB 
with a LC/MSD-TOF Agilent Technologies spectrometer, respectively. The HPLC 
measurements were performed using a HPLC Waters Alliance HT apparatus comprising 
a pump (Edwards RV12) with degasser, an autosampler, a diode array detector and a 
column as specified below. The reverse phase HPLC determinations were carried out on 
a YMC-Pack ODS-AQ column (50×4.6 mm,  D S. 3 µm, 12 nm). Solvent A: water with 
0.1% formic acid; Solvent B: acetonitrile with 0.1% formic acid, or solvent A: water 
with NH4HCO3, 10 mM pH 9.0; Solvent B: acetonitrile. Gradient: 5% of B to 100% of 
B within 3.5 min. Flux: 1.6 mL/min at 50 ºC. The analytical samples of all of the 
compounds that were subjected to pharmacological evaluation were dried at 65 ºC / 2 
Torr (standard conditions) at least for 2 days and possess a purity ≥95% as evidenced by 
their elemental analyses and HPLC measurements. Of note, as previously reported for 
 14
some tacrine-related dimeric compounds [31], the new hybrids herein described have 
the ability to retain molecules of water, which cannot be removed after drying the 
analytical samples under the aforementioned standard conditions. Thus, the elemental 
analyses of these compounds showed the presence of variable amounts of water, which 
have been indicated in the corresponding compound formulas. 
 
4.1.1. N-{3-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]propyl}-5-(4-
chlorophenyl)-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine-9-carboxamide 5a 
A solution of ester 6 (4.79 g, 10.2 mmol) and KOH pellets (85% purity, 2.04 g, 30.9 
mmol) in MeOH (260 mL) was stirred under reflux for 24 h. The resulting mixture was 
cooled to room temperature and evaporated to dryness. The solid residue was treated 
with an Et2O solution of HCl (1.2 N, 171 mL, 205 mmol) for 30 min and the resulting 
suspension was evaporated at reduced pressure, to give the corresponding 
tetrahydrobenzo[h][1,6]naphthyridinecarboxylic acid, in the form of its hydrochloride 
salt (6.54 g), which was directly used in the next step without further purification: IR 
(ATR) ν 3500–2500 (max at 3316, 2966, O–H, +N–H, C–H st), 1679, 1584, 1574 (C=O, 
Ar–C–C, Ar–C–N st) cm–1; 1H NMR (400 MHz, CD3SO) δ 1.28 [s, 9H, NCOO-
C(CH3)3], 1.76 (m, 2H, 3-H2), 2.66 (t, J= 5.6 Hz, 2H, 4-H2), 3.41 (m, 2H, 2-H2), 7.49 (d, 
J≈8.4 H, 2H), 7.64 (d, J=8.4 H, 2H) [2(6)-H and 3(5)-H 4-chlorophenyl], 7.78 (d, J=8.8 
Hz, 1H, 7-H), 8.17 (br d, J≈8.8 Hz, 1H, 8-H), 8.34 (br s, 1H, 10-H); HRMS (ESI), calcd 
for [C24H2335ClN2O4 + H +] 439.1419, found 439.1410. 
To a solution of crude tetrahydrobenzo[h][1,6]naphthyridinecarboxylic acid (298 mg) in 
EtOAc / DMF 10:1 (21 mL), Et3N (0.19 mL, 138 mg, 1.36 mmol), EDC (146 mg, 0.94 
mmol), and HOBt (128 mg, 0.94 mmol) were added, and the mixture was stirred at 
room temperature for 5 min. To the resulting mixture, amine 7a (200 mg, 0.69 mmol) 
was added and the reaction mixture was stirred at room temperature for 18 h and 
concentrated at reduced pressure, to give a semisolid residue (1.18 g), which was 
purified by column chromatography (35–70 µm silica gel, CH2Cl2/MeOH/50% aq. 
NH4OH mixtures, gradient elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH 
99.5:0.5:0.2 to 99.2:0.8:0.2, N1-Boc-protected amide (141 mg, 43% overall yield from 
6) and the final amide 5a (111 mg, 39% overall yield from 6) were successively isolated 
as yellowish solids. 
A solution of the N1-Boc-protected amide (141 mg, 0.20 mmol) in 4 M HCl / dioxane 
(2.41 mL, 9.64 mmol) was stirred thoroughly at room temperature for 18 h, and was 
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evaporated at reduced pressure. The resulting solid residue was diluted with H2O (3 
mL) and alkalinized with 10% aqueous Na2CO3 (2 mL). The alkaline solution was 
extracted with CHCl3 / MeOH 9:1 (4×25 mL) and the combined organic extracts were 
dried over anhydrous Na2SO4, and evaporated at reduced pressure to give amide 5a (115 
mg, 41% overall yield from 6, 80% total overall yield of 5a) as a yellowish solid; Rf 
0.65 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of amide 5a (95 mg, 0.16 mmol) in MeOH (5 mL) was filtered through a 
0.45 µm PTFE filter and treated with a methanolic solution of HCl (0.53 N, 2.6 mL, 
1.38 mmol). The resulting solution was evaporated at reduced pressure and the solid 
was washed with pentane to give, after drying under standard conditions, 5a·2HCl (95 
mg) as a yellowish solid: mp 295–297 ºC (MeOH); IR (ATR) ν 3500–2500 (max at 
3315, 3231, 3084, 3034, 2941, 2865, 2772, N–H, +N–H, C–H st), 1643, 1632, 1578, 
1553, 1514 (C=O, Ar–C–C, Ar–C–N st) cm–1; 1H NMR (500 MHz, CD3OD) δ 1.94–
2.02 (complex signal, 4H, 2”-H2, 3”-H2), superimposed in part 2.00 (tt, J≈J’≈ 6.0 Hz, 
2H, 3-H2), 2,20 (tt, J≈J’≈6.5 Hz, 2H, 2’-H2), 2.76 (t, J≈6.0 Hz, 2H, 4-H2), superimposed 
in part 2.78 (m, 2H, 1”-H2), 2,99 (t, J=6.5 Hz, 2H, 4”-H2), 3.61 (t, J=6.5 Hz, 2H, 1’-H2), 
3.73 (t, J=6.0 Hz, 2H, 2-H2), 4.13 (t, J=6.5 Hz, 2H, 3’-H2), 4.85 (s, NH, +NH), 7.47 (dd, 
J=9.0 Hz, J’=2.0 Hz, 1H, 7”-H), 7.64 (d, J=2.0 Hz, 1H, 5”-H), 7.65 (dm, J≈9.0 Hz, 2H) 
and 7.68 (dm, J=9.0 Hz, 2H) [2(6)-H and 3(5)-H 4-chlorophenyl], 7.85 (d, J=8.5 Hz, 
1H, 7-H), 8.20 (dd, J=8.5 Hz, J’=1.5 Hz, 1H, 8-H), 8.41 (d, J≈9.0 Hz, 1H, 8”-H), 8.96 
(d, J=1.5 Hz, 1H, 10-H); 13C NMR (125.8 MHz, CD3OD) δ 20.0 (CH2, C3), 21.7 (CH2, 
C3”), 22.9 (CH2, C2”), 24.9 (CH2, C1”), 25.0 (CH2, C4), 29.4 (CH2, C4”), 31.1 (CH2, 
C2’), 37.9 (CH2, C1’), 43.0 (CH2, C2), 46.3 (CH2, C3’), 110.0 (C, C4a), 113.7 (C, 
C9a”), 115.5 (C, C8a”), 116.1 (C, C10a) 119.0 (CH, C5”), 121.0 (CH, C7), 123.8 (CH, 
C10), 126.7 (CH, C7”), 128.7 (CH, C8”), 130.5 (2CH) and 131.8 (2CH) [C2(6) and 
C3(5) 4-chlorophenyl], 132.3 (C, C1 4-chlorophenyl), 132.5 (CH, C8), 132.8 (C, C9), 
138.3 (C, C4 4-chlorophenyl), 139.9 (C, C6”), 140.3 (C, C6a), 140.4 (C, C10a”), 151.6 
(C, C5), 152.3 (C, C4a”), 155.8 (C, C10b), 158.2 (C, C9”), 168.2 (C, CONH); HRMS 
(ESI), calcd for [C35H3335Cl2N5O + H +] 610.2135, found 610.2129; Anal. 
C35H33Cl2N5O·2HCl·1.5H2O (C, H, N). 
 
4.1.2. N-{4-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]butyl}-5-(4-chlorophenyl)-
1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine-9-carboxamide 5b 
 16
It was prepared as described for 5a. Starting from crude 
tetrahydrobenzo[h][1,6]naphthyridinecarboxylic acid (570 mg) and amine 7b (401 mg, 
1.32 mmol), a semisolid residue (2.54 g) was obtained and purified by column 
chromatography (35–70 µm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, 
gradient elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH 99:1:0.2, N1-Boc-
protected amide (307 mg, 48% overall yield from 6) and a 1:1 mixture of this amide 
with starting amine 7b (1H NMR) (234 mg, 18% overall yield of the protected amide 
from 6; 66% total overall yield of protected amide from 6) were successively isolated. 
Treatment of the N1-Boc-protected amide (272 mg, 0.38 mmol) with 4 M HCl / dioxane 
(2.51 mL, 10.0 mmol) as described for 5a afforded amide 5b (237 mg, 66% overall 
yield from 6) as a yellowish solid; Rf 0.67 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of amide 5b (237 mg, 0.38 mmol) in CH2Cl2 (10 mL) was filtered through a 
0.45 µm PTFE filter and treated with a methanolic solution of HCl (0.53 N, 6.3 mL, 
3.34 mmol). The resulting solution was evaporated at reduced pressure and the solid 
was washed with pentane to give, after drying under standard conditions, 5b·2HCl (285 
mg) as a yellowish solid: mp 276–279 ºC (CH2Cl2/MeOH 5:3); IR (ATR) ν 3500–2500 
(max. at 3226, 3062, 3028, 2937, 2871, 2803, N–H, +N–H, C–H st), 1651, 1632, 1586, 
1573, 1538 (C=O, Ar–C–C, Ar–C–N st) cm–1; 1H NMR (500 MHz, CD3OD) δ 1.84 (tt, 
J≈J’≈7,0 Hz, 2H, 2’-H2), 1,92–2,03 (complex signal, 8H, 3-H2, 3’-H2, 2”-H2 and 3”-
H2), 2,71 (t, J=6.0 Hz, 2H, 1”-H2), 2.76 (t, J=6.0 Hz, 2H, 4-H2), 2.98 (t, J=6.0 Hz, 2H, 
4”-H2), 3,52 (t, J=7.0 Hz, 2H, 1’-H2), 3.72 (t, J=6.0 Hz, 2H, 2-H2), 4.05 (t, J=7.0 Hz, 
2H, 4’-H2), 4.85 (s, NH, +NH), 7.50 (dd, J=9.5 Hz, J’=2.5 Hz, 1H, 7”-H), 7.66–7.70 
[complex signal, 5H, 2(6)-H and 3(5)-H 4-chlorophenyl, and 5”-H], 7.84 (d, J≈9.0 Hz, 
1H, 7-H), 8.22 (dd, J=9.0 Hz, J’=2.0 Hz, 1H, 8-H), 8.40 (d, J=9.5 Hz, 1H, 8”-H), 8.98 
(d, J≈2.0 Hz, 1H, 10-H); 13C NMR (125.8 MHz, CD3OD) δ 20.0 (CH2, C3), 21.7 (CH2, 
C3”), 22.9 (CH2, C2”), 24.7 (CH2, C1”), 25.0 (CH2, C4), 27.3 (CH2) and 28.7 (CH2) 
C2’, C3’), 29.3 (CH2, C4”), 40.7 (CH2, C1’), 43.0 (CH2, C2), 48.8 (CH2, C4’), 109.9 (C, 
C4a), 113.6 (C, C9a”), 115.5 (C, C8a”), 116.2 (C, C10a), 119.0 (CH, C5”), 120.9 (CH, 
C7), 123.7 (CH, C10), 126.8 (CH, C7”), 128.9 (CH, C8”), 130.4 (2CH) and 131.8 
(2CH) [C2(6) and C3(5) 4-chlorophenyl], 132.3 (C, C1 4-chlorophenyl), 132.5 (CH, 
C8), 133.2 (C, C9), 138.3 (C, C4 4-chlorophenyl), 140.0 (C, C6”), 140.3 (C, C6a), 
140.5 (C, C10a”), 151.6 (C, C5), 152.1 (C, C4a”), 155.7 (C, C10b), 157.9 (C, C9”), 
167.9 (C, CONH); HRMS (ESI), calcd for [C36H3535Cl2N5O + H +] 624.2291, found 
624.2274; Anal. C36H35Cl2N5O·2HCl·1.5H2O (C, H, N). 
 17
 
4.1.3. N-{5-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]pentyl}-5-(4-
chlorophenyl)-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine-9-carboxamide 5c 
It was prepared as described for 5a. Starting from crude 
tetrahydrobenzo[h][1,6]naphthyridinecarboxylic acid (190 mg) and amine 7c (141 mg, 
0.44 mmol), a semisolid residue (1.34 g) was obtained and purified by column 
chromatography (35–70 µm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, 
gradient elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH 99.2:0.8:0.2 to 
99:1:0.2, impure N1-Boc-protected amide (51 mg) and deprotected amide 5c (65 mg, 
34% overall yield from 6) were successively isolated as yellowish solids; Rf 0.71 
(CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of amide 5c (65 mg, 0.10 mmol) in CH2Cl2 (10 mL) was filtered through a 
0.45 µm PTFE filter and treated with a methanolic solution of HCl (0.53 N, 1.6 mL, 
0.85 mmol). The resulting solution was evaporated at reduced pressure and the solid 
was washed with pentane to give, after drying under standard conditions, 5c·2HCl (32 
mg) as a yellowish solid: mp 207–208 ºC (CH2Cl2/MeOH 20:3); IR (ATR) ν 3500–2500 
(max. at 3376, 3062, 2927, 2860, N–H, +N–H, C–H st), 1625, 1614, 1587, 1541, 1519 
(C=O, Ar–C–C, Ar–C–N st) cm–1; 1H NMR (500 MHz, CD3OD) δ 1.30 (m, 2H, 3’-H2), 
1.58 (tt, J≈ J’≈6.5 Hz, 2H, 2’-H2), 1.77 (m, 2H, 4’-H2), 1.90–2.02 (complex signal, 4H, 
2”-H2, 3”-H2), superimposed in part 1.99 (tt, J≈J’≈5.0 Hz, 2H, 3-H2), 2.69 (m, 2H, 1”-
H2), 2.76 (t, J=6.0 Hz, 2H, 4-H2), 2.98 (m, 2H, 4”-H2), 3.49 (td, J=7.0 Hz, J’=6.5 Hz, 
2H, 1’-H2), 3.72 (t, J=5.0 Hz, 2H, 2-H2), 3.98 (t, J=7.0 Hz, 2H, 5’-H2), 4.84 (s, NH, 
+NH), 7.50 (br d, J≈9.0 Hz, 1H, 7”-H), 7.66–7.72 [complex signal, 4H, 2(6)-H and 3(5)-
H 4-chlorophenyl], 7.73 (d, J=1.5 Hz, 1H, 5”-H), 7.86 (d, J=9.0 Hz, 1H, 7-H), 8.24 (d, 
J=9.0 Hz, 1H, 8-H), 8.39 (d, J=9.0 Hz, 1H, 8”-H), 8.66 (m, 1H, CONH), 9.02 (br s, 1H, 
10-H); 13C NMR (125.8 MHz, CD3OD) δ 20.0 (CH2, C3), 21.7 (CH2, C3”), 22.9 (CH2, 
C2”), 24.9 (CH2, C1”), 25.0 (CH2, C4), 25.6 (CH2, C3’), 29.4 (CH2, C4”), 29.9 (CH2) 
and 30.9 (CH2) (C2’, C4’), 40.8 (CH2, C1’), 43.0 (CH2, C2), 49.0 (CH2, C5’), 109.8 (C, 
C4a), 113.4 (C, C9a”), 115.5 (C, C8a”), 116.1 (C, C10a), 119.0 (CH, C5”), 120.9 (CH, 
C7), 123.6 (CH, C10), 126.8 (CH, C7”), 128.7 (CH, C8”), 130.4 (2CH) and 131.9 
(2CH) [C2(6) and C3(5) 4-chlorophenyl], 132.3 (C, C1 4-chlorophenyl), 132.7 (CH, 
C8), 133.3 (C, C9), 138.3 (C, C4 4-chlorophenyl), 140.0 (C, C6”), 140.2 (C, C6a), 
140.4 (C, C10a”), 151.5 (C, C5), 152.2 (C, C4a”), 155.7 (C, C10b), 157.8 (C, C9”), 
167.9 (C, CONH), an extra peak at 40.1 ppm was observed; HRMS (ESI), calcd for 
 18
[C37H3735Cl2N5O + H +] 638.2448, found 638.2435; Anal. C37H37Cl2N5O·2HCl·3H2O 
(C, H, N). 
 
4.1.4. N-{8-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]octyl}-5-(4-chlorophenyl)-
1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine-9-carboxamide 5d 
It was prepared as described for 5a. Starting from crude 
tetrahydrobenzo[h][1,6]naphthyridinecarboxylic acid (480 mg) and amine 7d (400 mg, 
1.11 mmol), a semisolid residue (2.45 g) was obtained and purified by column 
chromatography (35–70 µm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, 
gradient elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH 100:0:1, N1-Boc-
protected amide (370 mg, 63% overall yield from 6) was isolated as a yellowish solid. 
Treatment of the N1-Boc-protected amide (370 mg, 0.47 mmol) with 4 M HCl / dioxane 
(3.10 mL, 12.4 mmol) as described for 5a afforded amide 5d (359 mg, 63% overall 
yield from 6) as a yellowish solid; Rf 0.78 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of amide 5d (359 mg, 0.53 mmol) in CH2Cl2 (10 mL) was filtered through a 
0.45 µm PTFE filter and treated with a methanolic solution of HCl (0.53 N, 8.73 mL, 
4.63 mmol). The resulting solution was evaporated at reduced pressure and the solid 
was washed with pentane to give, after drying under standard conditions, 5d·2HCl (283 
mg) as a yellowish solid: mp 203–204 ºC (CH2Cl2/MeOH 5:4); IR (ATR) ν 3500–2500 
(max. at 3228, 3039, 2929, 2860, N–H, +N–H, C–H st), 1731, 1631, 1573 (C=O, Ar–C–
C, Ar–C–N st) cm–1; 1H NMR (500 MHz, CD3OD) δ 1.38–1.50 (complex signal, 8H, 
3’-H2, 4’-H2, 5’-H2, 6’-H2), 1.69 (tt, J≈J’≈7.5 Hz, 2H, 2’-H2), 1.85 (tt, J≈J’≈7.5 Hz, 2H, 
7’-H2), 1.92–2.00 (complex signal, 6H, 3-H2, 2”-H2, 3”-H2), 2.68 (t, J=6.0 Hz, 2H, 1”-
H2), 2.75 (t, J=6.5 Hz, 2H, 4-H2), 3.01 (t, J=6.0 Hz, 2H, 4”-H2), 3.43 (t, J=7.5 Hz, 2H, 
1’-H2), 3.71 (t, J=6.0 Hz, 2H, 2-H2), 3.95 (t, J=7.5 Hz, 2H, 8’-H2), 4.85 (s, NH, +NH), 
7.55 (dd, J=9.5 Hz, J’=2.0 Hz, 1H, 7”-H), 7.67 [complex signal, 4H, 2(6)-H and 3(5)-H 
4-chlorophenyl], 7.78 (d, J=2.0 Hz, 1H, 5”-H), 7.87 (d, J=9.0 Hz, 1H, 7-H), 8.25 (dd, 
J=9.0 Hz, J’=2.0 Hz, 1H, 8-H), 8.38 (d, J=9.5 Hz, 1H, 8”-H), 8.99 (d, J≈2.0 Hz, 1H, 10-
H); 13C NMR (125.8 MHz, CD3OD) δ 20.0 (CH2, C3), 21.8 (CH2, C3”), 22.9 (CH2, 
C2”), 24.8 (CH2, C1”), 25.0 (CH2, C4), 27.6 (CH2, C6’), 28.0 (CH2, C3’), 29.3 (CH2, 
C4”), 30.1 (CH2) and 30.2 (CH2) (C4’, C5’), 30.4 (CH2, C2’), 31.3 (CH2, C7’), 41.3 
(CH2, C1’), 43.0 (CH2, C2), 49.2 (CH2, C8’), 109.8 (C, C4a), 113.3 (C, C9a”), 115.4 (C, 
C8a”), 116.1 (C, C10a), 119.1 (CH, C5”), 120.9 (CH, C7), 123.6 (CH, C10), 126.7 (CH, 
C7”), 128.8 (CH, C8”), 130.4 (2CH) and 131.9 (2CH) [C2(6) and C3(5) 4-
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chlorophenyl], 132.2 (C, C1 4-chlorophenyl), 132.6 (CH, C8), 133.5 (C, C9), 138.3 (C, 
C4 4-chlorophenyl), 140.1 (C, C6”), 140.2 (C, C6a), 140.5 (C, C10a”), 151.4 (C, C5), 
152.1 (C, C4a”), 155.7 (C, C10b), 157.8 (C, C9”), 167.9 (C, CONH); HRMS (ESI), 
calcd for [C40H4335Cl2N5O + H +] 680.2917, found 680.2900; Anal. 
C40H43Cl2N5O·2HCl·2.5H2O (C, H, N). 
 
4.2. Biological assays 
4.2.1. Determination of AChE and BChE inhibitory activities 
The inhibitory activities against human recombinant AChE (Sigma-Aldrich) and human 
serum BChE (Sigma-Aldrich) were evaluated spectrophotometrically by the method of 
Ellman et al. [15]. The reactions took place in a final volume of 300 µL of 0.1 M 
phosphate-buffered solution pH 8.0, containing hAChE (0.02 u/mL) or hBChE (0.02 
u/mL) and 333 µM 5,5'-dithiobis(2-nitrobenzoic) acid (DTNB; Sigma-Aldrich) solution 
used to produce the yellow anion of 5-thio-2-nitrobenzoic acid. Inhibition curves were 
performed in duplicates using at least 10 increasing concentrations of inhibitors and 
preincubated for 20 min at 37 ºC before adding the substrate [32]. One duplicate sample 
without inhibitor was always present to yield 100% of AChE or BChE activities. Then 
substrates, acetylthiocholine iodide (450 µM; Sigma-Aldrich) or butyrylthiocholine 
iodide (300 µM; Sigma-Aldrich), were added and the reaction was developed for 5 min 
at 37 ºC. The colour production was measured at 414 nm using a labsystems Multiskan 
spectrophotometer.  
Data from concentration−inhibition experiments of the inhibitors were calculated by 
non-linear regression analysis, using the GraphPad Prism program package (GraphPad 
Software; San Diego, USA), which gave estimates of the IC50 (concentration of drug 
producing 50% of enzyme activity inhibition). Results are expressed as mean ± S.E.M. 
of at least 4 experiments performed in duplicate.  
 
4.2.2. Determination of Aβ42 and tau aggregation inhibitory activities in intact 
Escherichia coli cells  
Cloning and overexpression of Aβ42 peptide: Escherichia coli competent cells BL21 
(DE3) were transformed with the pET28a vector (Novagen, Inc., Madison, WI, USA) 
carrying the DNA sequence of Aβ42. Because of the addition of the initiation codon 
ATG in front of both genes, the overexpressed peptide contains an additional 
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methionine residue at its N terminus. For overnight culture preparation, 10 mL of 
lysogeny broth (LB) medium containing 50 µg·mL–1 of kanamycin were inoculated 
with a colony of BL21 (DE3) bearing the plasmid to be expressed at 37 °C. After 
overnight growth, the OD600 was usually 2–2.5. For expression of Aβ42 peptide, 20 µL 
of overnight culture were transferred into eppendorf tubes of 1.5 mL containing 960 µL 
of LB medium with 50 µg·mL–1 of kanamycin, 1 mM of isopropyl 1-thio-β-D-
galactopyranoside (IPTG), 10 µL of a 10 µM solution of each hybrid 5 or reference 
compound in DMSO, and 10 µL of a 25 µM solution of Th-S in water. The samples 
were grown for 24 h at 37 °C and 1400 rpm using a Thermomixer (Eppendorf, 
Hamburg, Germany). In the negative control (without drug) the same amount of DMSO 
was added in the sample. 
Cloning and overexpression of tau protein: E. coli BL21 (DE3) competent cells were 
transformed with pTARA containing the RNA-polymerase gen of T7 phage (T7RP) 
under the control of the promoter pBAD. E. coli BL21 (DE3) with pTARA competent 
cells were transformed with pRKT42 vector encoding four repeats of tau protein in two 
inserts. For overnight culture preparation, 10 mL of M9 medium containing 0.5% of 
glucose, 50 µg·mL–1 of ampicillin and 12.5 µg·mL–1 of chloramphenicol were 
inoculated with a colony of BL21 (DE3) bearing the plasmids to be expressed at 37 °C. 
After overnight growth, the OD600 was usually 2–2.5. For expression of tau protein, 20 
µL of overnight culture were transferred into eppendorf tubes of 1.5 mL containing 970 
µL of M9 medium containing 0.25% of arabinose, 0.5% of glucose, 50 µg·mL–1 of 
ampicillin and 12.5 µg·mL–1 of chloramphenicol, 10 µL of a 10 µM solution of each 
hybrid 5 or reference compound in DMSO, and 10 µL of a 25 µM solution of Th-S in 
water. The samples were grown for 24 h at 37 °C and 1400 rpm using a Thermomixer 
(Eppendorf, Hamburg, Germany). In the negative control (without drug) the same 
amount of DMSO was added in the sample. 
Th-S steady-state fluorescence: Th-S (T1892) and other chemical reagents were 
purchased from Sigma (St. Louis, MO). Th-S stock solution (2.5 mM) was prepared in 
double-distilled water purified through a Milli-Q system (Millipore, USA). Fluorescent 
spectral scans of Th-S were analyzed using an Aminco Bowman Series 2 luminescence 
spectrophotometer (Aminco-Bowman AB2, SLM Aminco, Rochester, NY, USA). 
Excitation and emission slit widths of 4 nm were used. Finally, the fluorescence 
emission at 455 nm, when exciting at 375 nm, was recorded. In order to normalize the 
Th-S fluorescence as a function of the bacterial concentration, OD600 was obtained 
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using a Shimadzu UV-2401 PC UV–Vis spectrophotometer (Shimadzu, Japan). The 
final fluorescence data were obtained considering as 100% the Th-S fluorescence of the 
bacterial cells expressing the peptide or protein in the absence of drug and 0% the Th-S 
fluorescence of the bacterial cells non-expressing the peptide or protein. Final data are 
the average of ten independent experiments. 
 
4.2.3. PAMPA-BBB assay 
To evaluate the brain penetration of hybrids 5, a parallel artificial membrane permeation 
assay for blood–brain barrier was used, following the method described by Di et al. 
[28]. The in vitro permeability (Pe) of fourteen commercial drugs through lipid extract 
of porcine brain membrane together with the test compounds was determined. 
Commercial drugs and the synthesized compounds were tested using a mixture 
PBS:EtOH 70:30. Assay validation was made by comparing the experimental 
permeability of the different compounds with the reported bibliography values of the 
commercial drugs, which showed a good correlation: Pe (exp) = 1.5010 Pe (lit) − 0.8618 
(R2 = 0.9199). From this equation and taking into account the limits established by Di et 
al. for BBB permeation, we established the ranges of permeability as compounds of 
high BBB permeation  (CNS+): Pe (10−6 cm s−1) > 5.1; compounds of low BBB 
permeation (CNS−): Pe (10−6 cm s−1) < 2.1, and  compounds of uncertain BBB 
permeation (CNS+/−): 5.1 > Pe (10−6 cm s−1) > 2.1. 
 
4.3. Molecular modelling 
4.3.1. Setup of the system. Molecular modelling was performed using the X-ray 
crystallographic structure of hAChE in complex with huprine W (PDB ID: 4BDT [15]). 
The structure was refined by removal of N-acetyl-D-glucosamine and sulphate anions 
and addition of missing hydrogen atoms. The enzyme was modelled in its physiological 
active form with neutral His447 and deprotonated Glu334, which together with Ser203 
form the catalytic triad. The ionization state for the rest of ionizable residues was 
assessed from PROPKA3 [33] calculations. Accordingly, the standard ionization state at 
neutral pH was considered but for residues Glu285, Glu450 and Glu452, which were 
protonated. Finally, three disulfide bridges were defined between Cys residues 257–272, 
529–409, and 69–96, respectively. 
4.3.2. Molecular dynamics simulations. The binding mode of hybrid 5a to hAChE was 
explored by means of MD simulations.  Starting from that proposed initial pose, a 100 
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ns MD simulation was performed using the PMEMD module of AMBER12 [34] 
software package, the parm99SB [35] force field for the protein and the GAFF-derived 
parameters [36] for the ligand, whose geometrical parameters were optimized at the 
B3LYP/6-31G(d) level [37] and its charge distribution was described by using 
electrostatic potential charges with the RESP procedure [38]. Na+ cations were added to 
neutralize the negative charge of the system with the XLEAP module of AMBER12. 
The system was immersed in an octahedral box of TIP3P [39] water molecules, 
preserving the crystallographic waters inside the binding cavity. The final system 
contained around 52000 atoms. 
The geometry of the system was minimized in four steps. First, water molecules and 
counterions were refined through 7000 steps of conjugate gradient and 3000 steps of 
steepest descent algorithm. Then, the position of hydrogen atoms was optimized using 
4500 steps of conjugate gradient and 500 steps of steepest descent algorithm. At the 
third stage, hydrogen atoms, water molecules and counterions were further optimized 
using 11500 steps of conjugate gradient and 2500 steps of steepest descent algorithm. 
Thermalization of the system was performed in five steps of 25 ps, increasing the 
temperature from 50 to 298 K. Concomitantly, the residues that define the binding site 
were restrained during thermalization using a variable restraining force. Thus, a force 
constant of 25 kcal mol –1Å–2 was used in the first stage of the thermalization and was 
subsequently decreased by increments of 5 kcal mol –1Å–2 in the next stages. Then, an 
additional step of 250 ps was performed in order to equilibrate the system density at 
constant pressure (1 bar) and temperature (298 K). Finally, a 100 ns trajectory was run 
using a time step of 2 fs. SHAKE was used for those bonds containing hydrogen atoms 
in conjunction with periodic boundary conditions at constant volume and temperature, 
particle mesh Ewald for the treatment of long electrostatic interactions, and a cutoff of 
10 Å for nonbonded interactions. Moreover, in the initial 20 ns of the simulation the 
distance between the protonated nitrogen in the 6-chlorotacrine moiety of the inhibitor 
and the carbonyl oxygen of His447 was constrained to avoid artefactual rearrangements 
in the CAS of the enzyme. 
The structural analysis was performed using in-house software and standard codes of 
AMBER12. The solvent interaction energies (SIE) technique developed by Purisima 
and co-workers [19] was used to estimate the interaction free energies for the AChE 
inhibitor. Calculations were performed for a set of 200 snapshots taken along the last 40 
ns of the MD trajectory. 
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Table, Figures, and Scheme Legends 
 
Table 1. Inhibitory activities of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine–6-
chlorotacrine hybrids and reference compounds against AChE, BChE, Aβ42 and tau 
aggregation, and BBB predicted permeabilities. 
 
Table 2. In silico prediction of ADMET properties for hybrids 5a–d and the reference 
compound tacrine. 
 
Fig. 1. Rational design of the tetrahydrobenzo[h][1,6]naphthyridine–6-chlorotacrine 
hybrid 5a. 
 
Fig. 2. Superimposition of the MD-predicted binding mode of 
tetrahydrobenzo[h][1,6]naphthyridine 4 in AChE with the X-ray structure of the 
complex Torpedo californica AChE–tacrine. 
 
Fig. 3. Representation of the binding mode of the 
tetrahydrobenzo[h][1,6]naphthyridine–6-chlorotacrine hybrid 5a (magenta) in the 
average structure obtained from the snapshots sampled in the last 5 ns of the trajectory. 
The residues involved in interactions are shown as green-coloured sticks. 
 
Scheme 1. Synthesis of the target tetrahydrobenzo[h][1,6]naphthyridine–6-chlorotacrine 
hybrids. 
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Table 1. Inhibitory activities of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine–6-
chlorotacrine hybrids and reference compounds against AChE, BChE, Aβ42 and tau 
aggregation, and BBB predicted permeabilities. 
Compd hAChE 
IC50 (nM)a 
hBChE  
IC50 (nM)a 
Aβ42 
aggregation 
in E. coli 
(% inhib. 
at 10 µM)b 
Tau protein 
aggregation 
in E. coli  
(% inhib. 
at 10 µM)b 
Pe (10–6 cm s–6)c 
(Prediction) 
5a 0.006 ± 0.002 120 ± 13 52.5 ± 0.4 40.7 ± 0.5 10.5 ± 0.7 (CNS+) 
5b 14.2 ± 1.7 205 ± 16 55.8 ± 0.7 58.9 ± 0.4 13.8 ± 0.4 (CNS+) 
5c 14.2 ± 1.9 337 ± 30 54.3 ± 0.7 57.7 ± 0.5 14.3 ± 1.3 (CNS+) 
5d 2.06 ± 0.3 286 ± 35 77.5 ± 0.9 68.7 ± 0.5 19.2 ± 1.3 (CNS+) 
1 nad nad 41.8 ± 0.4 27.9 ± 1.2 9.9 ± 1.4 (CNS+) 
2 5.9 ± 0.6 114 ± 4 11.0 ± 0.6 1.4 ± 0.7 19.8 ± 0.4 (CNS+)e 
3 19.3 ± 1.4 223 ± 35 54.6 ± 0.5 37.8 ± 0.5 13.9 ± 0.8 (CNS+) 
4 65.0 ± 3.0f 920 ± 30f ndg ndg 22.9 ± 0.8 (CNS+)f 
a
 IC50 inhibitory concentration (nM) of human recombinant AChE and human serum 
BChE. IC50 values are expressed as mean ± standard error of the mean (SEM) of at least 
four experiments (n = 4), each performed in duplicate. 
b
 % Inhibition of Aβ42 and tau protein aggregation at 10 µM in intact E. coli cells. 
Values are expressed as mean ± SEM of four independent experiments (n = 4). 
c
 Permeability values from the PAMPA-BBB assay. Values are expressed as the mean ± 
SD of three independent experiments (n = 3). 
d
 Not active. 
e
 Data from [9]. 
f
 Data from [10]. 
g
 Not determined. 
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Table 2. In silico prediction of ADMET properties for hybrids 5a–d and the reference 
compound tacrine. 
 
Compd Blood–brain 
barrier 
permeation 
Intestinal 
absorption 
Rat acute toxicity 
LD50 (mg/kg) 
5a + + 566 
5b + + 449 
5c + + 803 
5d + + 493 
Tacrine + + 75  (70)a 
 
a
 Taken from ref. 30. 
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5
9
1
N
X
Cl
XO
1, X = O
IC50 (hAChE) > 10 µM
IC50 (hBChE) > 10 µM
HN N
H
N
Cl
n
N
X
Cl
O
4, X = NH
IC50 (hAChE) = 65 nM
IC50 (hBChE) = 920 nM
optimization of PAS-binding moiety
3, X = O; n = 8
IC50 (hAChE) = 19 nM
IC50 (hBChE) = 223 nM
molecular hybridization
molecular hybridization
optimization of tether length
5a, X = NH; n = 3
optimization of PAS-binding moiety
optimization of tether length
H2N
N
Cl
6-chlorotacrine, 2
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N
N
CO2Et
Cl
6
1) a) KOH, MeOH; b) HCl, Et2O
2) a) HOBt, EDC, Et3N, EtOAc/DMF
    
    b)
Boc
H2N NH
N
Cl
n
7a-d
HN N
H
N
Cl
n
N
H
N
Cl
O
5a-d
a, n = 3; b, n = 4; c, n = 5; d, n = 8
3) 4 M HCl / dioxane
2
3
4 5
7
8
9 1" 2"
3"
4"
5"
6"
7"
8"
9"
10"
10
1' n'
1
6
 
 
